BriaCell Therapeutics Corp. (Nasdaq: BCTX), a clinical-stage biotechnology company focused on innovative cancer immunotherapies, has announced two upcoming virtual investor presentations. The events are scheduled for Thursday, June 12, and Thursday, June 26, 2025, both at 12:00 PM EDT. The presentations, organized by Renmark Financial Communications Inc., will be accessible to stakeholders, investors, and other interested parties through online registration. While live event participation may be limited, replays will be available on the Company's Investor website. Participants are advised to use the latest version of Google Chrome for optimal connectivity.
BriaCell Therapeutics Corp. (Nasdaq: BCTX), un'azienda biotecnologica in fase clinica specializzata in immunoterapie innovative contro il cancro, ha annunciato due prossime presentazioni virtuali per investitori. Gli eventi si terranno gioved矛 12 giugno e gioved矛 26 giugno 2025, entrambi alle 12:00 PM EDT. Le presentazioni, organizzate da Renmark Financial Communications Inc., saranno accessibili a stakeholder, investitori e altre parti interessate tramite registrazione online. La partecipazione in diretta potrebbe essere limitata, ma le registrazioni saranno disponibili sul sito web per gli investitori della Societ脿. Si consiglia ai partecipanti di utilizzare l'ultima versione di Google Chrome per una connettivit脿 ottimale.
BriaCell Therapeutics Corp. (Nasdaq: BCTX), una empresa biotecnol贸gica en etapa cl铆nica centrada en inmunoterapias innovadoras contra el c谩ncer, ha anunciado dos pr贸ximas presentaciones virtuales para inversionistas. Los eventos est谩n programados para el jueves 12 de junio y el jueves 26 de junio de 2025, ambos a las 12:00 PM EDT. Las presentaciones, organizadas por Renmark Financial Communications Inc., estar谩n disponibles para accionistas, inversionistas y otras partes interesadas mediante registro en l铆nea. La participaci贸n en vivo puede ser limitada, pero las repeticiones estar谩n disponibles en el sitio web de inversores de la Compa帽铆a. Se recomienda a los participantes usar la 煤ltima versi贸n de Google Chrome para una conectividad 贸ptima.
BriaCell Therapeutics Corp. (Nasdaq : BCTX), une soci茅t茅 biotechnologique en phase clinique sp茅cialis茅e dans les immunoth茅rapies innovantes contre le cancer, a annonc茅 deux prochaines pr茅sentations virtuelles pour investisseurs. Les 茅v茅nements sont pr茅vus le jeudi 12 juin et le jeudi 26 juin 2025, tous deux 脿 12h00 EDT. Organis茅es par Renmark Financial Communications Inc., ces pr茅sentations seront accessibles aux parties prenantes, investisseurs et autres int茅ress茅s via une inscription en ligne. La participation en direct peut 锚tre limit茅e, mais les rediffusions seront disponibles sur le site web investisseurs de la Soci茅t茅. Il est conseill茅 aux participants d'utiliser la derni猫re version de Google Chrome pour une connectivit茅 optimale.
BriaCell Therapeutics Corp. (Nasdaq: BCTX), ein biotechnologisches Unternehmen in der klinischen Entwicklungsphase mit Fokus auf innovative Krebsimmuntherapien, hat zwei bevorstehende virtuelle Investorenpr盲sentationen angek眉ndigt. Die Veranstaltungen sind f眉r Donnerstag, den 12. Juni, und Donnerstag, den 26. Juni 2025, jeweils um 12:00 Uhr EDT geplant. Die Pr盲sentationen, organisiert von Renmark Financial Communications Inc., sind f眉r Stakeholder, Investoren und andere Interessierte nach Online-Registrierung zug盲nglich. Die Live-Teilnahme k枚nnte begrenzt sein, aber Wiederholungen werden auf der Investorenseite des Unternehmens verf眉gbar sein. Teilnehmer werden empfohlen, die neueste Version von Google Chrome f眉r eine optimale Verbindung zu verwenden.
Positive
None.
Negative
None.
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (鈥�BriaCell鈥� or the 鈥�Company鈥�), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces today that the Company will be conducting two virtual investor presentations on Thursday, June 12, at 12:00 PM EDT and on Thursday, June 26, at 12:00 PM EDT, arranged by Renmark Financial Communications Inc. Briacell Therapeutics Corp. welcomes stakeholders, investors, and other individual followers to register and attend these live events.
Investors interested in participating in this event will need to register using the links below. As a reminder, registration for the live event may be limited but access to the replay after the event will be on the Company鈥檚 Investor website.
REGISTER HERE:
To ensure smooth connectivity, please access this link using the latest version of Google Chrome.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at .
Safe Harbor
This press release contains 鈥渇orward-looking statements鈥� that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements may be identified by the use of words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渟eek,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渢arget,鈥� 鈥渁im,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those specifying the date and time that the Company will be conducting the virtual investor presentations, are based on BriaCell鈥檚 current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading 鈥淩isks and Uncertainties鈥� in the Company鈥檚 most recent Management鈥檚 Discussion and Analysis, under the heading 鈥淩isk Factors鈥� in the Company鈥檚 most recent Annual Information Form, and under 鈥淩isks and Uncertainties鈥� in the Company鈥檚 other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company鈥檚 profiles on SEDAR+ at 听and on EDGAR at . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact: William V. Williams, MD President & CEO 1-888-485-6340 听
Investor Relations Contact:
FAQ
When are BriaCell's (BCTX) upcoming virtual investor presentations in June 2025?
BriaCell has scheduled two virtual investor presentations on Thursday, June 12, 2025, and Thursday, June 26, 2025, both at 12:00 PM EDT.
How can investors attend BriaCell's (BCTX) virtual presentations in June 2025?
Investors need to register online for the events. While live participation may be limited, replays will be available on BriaCell's Investor website.
What is BriaCell Therapeutics (BCTX) main business focus?
BriaCell Therapeutics is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.
Which stock exchanges is BriaCell (BCTX) listed on?
BriaCell is listed on the Nasdaq (under symbols BCTX, BCTXW, BCTXZ) and the Toronto Stock Exchange (under symbol BCT).
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, to receive support.
